HS
KNTE

HighVista Strategies’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

HighVista Strategies’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-46,264
Closed -$820K – 102
2021
Q4 		$820K Sell
46,264
-14,641
-24% -$309K 0.65% 56
2021
Q3 		$1.4M Buy
60,905
+27,514
+82% +$599K 0.93% 21
2021
Q2 		$777K Buy
+33,391
New +$850K 0.55% 56

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighVista Strategies's KNTE Position: Q1 2022 in Review

HighVista Strategies sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2022, closing a stake of 46,264 shares — an estimated $820K sold.

HighVista Strategies first reported a position in KNTE in Q2 2021 and held it in 3 quarters. The position peaked at $1.4M in Q3 2021. 76 funds tracked by Wall St. Rank hold KNTE as of Q1 2022.

  • HighVista Strategies reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • HighVista Strategies sold 46,264 Kinnate Biopharma Inc. Common Stock shares in Q1 2022, an estimated $820K.
  • HighVista Strategies first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • HighVista Strategies's Kinnate Biopharma Inc. Common Stock position peaked at $1.4M in Q3 2021.
  • 76 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2022.

Based on HighVista Strategies's 13F filing for Q1 2022, filed 16 May 2022.